Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 11/20 | 0.59 |
| ▸ | ADORA1 | P30542 | 9/20 | 0.59 |
| ▸ | PI4KA | P42356 | 10/20 | 0.54 |
| ▸ | PI4K2B | Q8TCG2 | 10/20 | 0.54 |
| ▸ | PI4K2A | Q9BTU6 | 10/20 | 0.54 |
| ▸ | PI4KB | Q9UBF8 | 10/20 | 0.54 |
| ▸ | ADORA2B | P29275 | 4/20 | 0.54 |
| ▸ | GSK3B | P49841 | 1/20 | 0.47 |
| ▸ | EGFR | P00533 | 1/20 | 0.47 |
| ▸ | AHCY | P23526 | 1/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5039983 | 0.75 | PI4KA (0.56) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL5144936 | 0.75 | ADORA2A (0.57) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL106573 | 0.75 | ADORA2A (1.00) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL580610 | 0.74 | ADORA2A (0.64) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL11457654 | 0.74 | ADORA2A (0.55) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL7140260 | 0.73 | ADORA2A (0.96) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL667204 | 0.72 | ADORA2A (0.62) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL28413958 | 0.72 | ADORA2A (0.62) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL6883849 | 0.72 | ADORA2A (0.61) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL27774840 | 0.72 | PI4KA (0.44) | ADORA2AADORA1PI4KAPI4K2BPI4K2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 815 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0805690-B1 | METHOD FOR SELECTIVE METHIONINE STARVATION OF MALIGNANT CELLS IN MAMMALS | UNIV CALIFORNIA (US) | 2002-08-07 | — | — | EP | claimed |
| US-20260024621-A1 | OLIGONUCLEOTIDE-BASED MACHINE LEARNING | CREYON BIO INC (US) | 2026-01-22 | — | — | US | disclosed |
| US-12527877-B2 | Anti-transferrin receptor antibodies, conjugates thereof, and uses thereof | Arrowhead Pharmaceuticals, Inc. (US) | 2026-01-20 | — | — | US | disclosed |
| US-12472199-B2 | P-ethoxy nucleic acids for IGF-1R inhibition | THOMAS JEFFERSON UNIVERSITY (US) | 2025-11-18 | — | — | US | disclosed |
| US-12400739-B2 | Oligonucleotide-based machine learning | CREYON BIO, INC. (US) | 2025-08-26 | — | — | US | disclosed |
| US-20250255897-A1 | P-ETHOXY NUCLEIC ACIDS FOR LIPOSOMAL FORMULATION | Bio-Path Holdings, Inc. (US) | 2025-08-14 | — | — | US | disclosed |
| US-20250235549-A1 | ANTI-TRANSFERRIN RECEPTOR ANTIBODIES, CONJUGATES THEREOF, AND USES THEREOF | Arrowhead Pharmaceuticals, Inc. | 2025-07-24 | — | — | US | disclosed |
| US-12319911-B2 | P-ethoxy nucleic acids for STAT3 inhibition | Bio-Path Holdings, Inc. (US) | 2025-06-03 | — | — | US | disclosed |
| US-12234457-B2 | P-ethoxy nucleic acids for BCL2 inhibition | Bio-Path Holdings, Inc. (US) | 2025-02-25 | — | — | US | disclosed |
| US-20240404636-A1 | OLIGONUCLEOTIDE-BASED MACHINE LEARNING | CREYON BIO, INC. | 2024-12-05 | — | — | US | disclosed |
| EP-0789577-A4 | SYNTHESIS OF N-SUBSTITUTED OLIGOMERS | CHIRON CORP (US) | 1998-07-22 | — | — | EP | disclosed |
| EP-0800526-A1 | METHOD FOR THE CONTROLLED SYNTHESIS OF POLYNUCLEOTIDE MIXTURES WHICH ENCODE DESIRED MIXTURES OF PEPTIDES | CHIRON CORPORATION (US) | 1997-10-15 | — | — | EP | disclosed |
| EP-0789577-A1 | SYNTHESIS OF N-SUBSTITUTED OLIGOMERS | CHIRON CORPORATION (US) | 1997-08-20 | — | — | EP | disclosed |
| EP-0777492-A1 | COMBINATORIAL LIBRARIES OF SUBSTRATE-BOUND CYCLIC ORGANIC COMPOUNDS | CHIRON CORPORATION (US) | 1997-06-11 | — | — | EP | disclosed |
| EP-0671928-A4 | SYNTHESIS OF N-SUBSTITUTED OLIGOMERS. | CHIRON CORP (US) | 1997-04-23 | — | — | EP | disclosed |
| WO-1996040202-A1 | SYNTHESIS OF N-SUBSTITUTED OLIGOMERS | CHIRON CORPORATION (US) | 1996-12-19 | — | — | WO | disclosed |
| WO-1996040201-A1 | COMBINATORIAL LIBRARIES OF SUBSTRATE-BOUND CYCLIC ORGANIC COMPOUNDS | CHIRON CORPORATION (US) | 1996-12-19 | — | — | WO | disclosed |
| WO-1996020947-A1 | METHOD FOR THE CONTROLLED SYNTHESIS OF POLYNUCLEOTIDE MIXTURES WHICH ENCODE DESIRED MIXTURES OF PEPTIDES | CHIRON CORPORATION (US) | 1996-07-11 | — | — | WO | disclosed |
| EP-0671928-A1 | SYNTHESIS OF N-SUBSTITUTED OLIGOMERS | CHIRON CORPORATION (US) | 1995-09-20 | — | — | EP | disclosed |
| WO-1994006451-A1 | SYNTHESIS OF N-SUBSTITUTED OLIGOMERS | CHIRON CORPORATION (US) | 1994-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260024621-A1 | OLIGONUCLEOTIDE-BASED MACHINE LEARNING | POLN, TOP1, NCL | ADORA2A 3374/4885ADORA1 1013/4885PI4KA 2368/4885 |
| US-12527877-B2 | Anti-transferrin receptor antibodies, conjugates thereof, and uses thereof | MUSK, TFRC, FTH1 | ADORA2A 4103/4885ADORA1 3680/4885PI4KA 3765/4885 |
| US-20250235549-A1 | ANTI-TRANSFERRIN RECEPTOR ANTIBODIES, CONJUGATES THEREOF, AND USES THEREOF | TFRC, MUSK, FOLR1 | ADORA2A 2102/4885ADORA1 840/4885PI4KA 4248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.